Pharmaceutical company Galderma has released new interim data from two ongoing investigator-initiated trials (IITs).
The IITs presented results from Sculptra, a regenerative biostimulator, and the hyaluronic acid injectable Restylane range in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for both the face and body. Conducted by plastic surgeon Dr Andreas Nikolis, new interim results from a nine-month clinical sequencing IIT of women in menopause, on both the face and the décolletage, demonstrated that the combination of Restylane Skinboosters and Sculptra drove progressive and meaningful improvement in skin quality.
The most pronounced gains in hydration were seen when using Restylane Skinboosters first. Results showed that facial hydration and measures of skin barrier function improved over time in both groups, with satisfaction scores rising consistently across the study and reaching high levels by month six.
A separate IIT conducted by cosmetic dermatologist Dr Sabrina Fabi evaluated 20 female patients with mild-to-moderate skin laxity on their abdomen. It showed that in patients experiencing aesthetic changes in the abdomen associated with medication-driven weight loss, the cellular composition of adipose tissue is altered. Interim results demonstrated a four-fold reduction in adipose-derived stem cells when compared to those who were not taking prescription weight-loss medication.
Dr Fabi commented, “The findings from this IIT suggest shifts in the skin and adipose-tissue profile that may help explain the volume-related changes clinicians are seeing. By clarifying the biological underpinnings, we can better guide treatment planning.” Dr Nikolis said, “This clinical study is helping address an important unmet need by generating objective data in a population that has historically been overlooked in aesthetic research.”